首页 > 最新文献

Journal of Clinical Oncology最新文献

英文 中文
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. 寡转移性胰腺导管腺癌(EXTEND)在全身治疗的基础上增加转移引导治疗:多中心、随机 II 期试验。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-08-05 DOI: 10.1200/JCO.24.00081
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, Marina N Medina-Rosales, Alexandre Reuben, Emma B Holliday, Grace L Smith, Sonal S Noticewala, Sarah Nicholas, Tracy R Price, Rachael M Martin-Paulpeter, Luis A Perles, Sunyoung S Lee, Michael S Lee, Brandon G Smaglo, Ryan W Huey, Jason Willis, Dan Zhao, Lorenzo Cohen, Cullen M Taniguchi, Eugene J Koay, Matthew H G Katz, Robert A Wolff, Prajnan Das, Shubham Pant, Albert C Koong, Chad Tang

Purpose: The EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).

Methods: EXTEND (ClinicalTrials.gov identifier: NCT03599765) is a multicenter, phase II basket trial randomly assigning patients with ≤five metastases 1:1 to MDT plus systemic therapy versus systemic therapy. Disease progression was defined by radiologic criteria (RECIST v1.1), clinical progression, or death. The primary end point was PFS in the per-protocol population, evaluated after all patients achieved at least 6 months of follow-up. Exploratory end points included systemic immune response measures.

Results: Between March 19, 2019, and February 13, 2023, 41 patients were randomly assigned and 40 were eligible for the primary analysis of PFS (19 patients in the MDT arm; 21 patients in the control arm). At a median follow-up time of 17 months, the median PFS time was 10.3 months (95% CI, 4.6 to 14.0) in the MDT arm versus 2.5 months (95% CI, 1.7 to 5.1) in the control arm. PFS was significantly improved by the addition of MDT to systemic therapy (P = .030 for stratified log-rank test) with a hazard ratio of 0.43 (95% CI, 0.20 to 0.94). No grade ≥3 or greater adverse events related to MDT were observed. Systemic immune activation events were associated with MDT and correlated with improved PFS.

Conclusion: This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.

目的:EXTEND试验检验了一种假设,即在化疗基础上增加综合转移导向疗法(MDT)将比单纯化疗改善寡转移性胰腺导管腺癌(PDAC)患者的无进展生存期(PFS):EXTEND(ClinicalTrials.gov标识符:NCT03599765)是一项多中心II期篮子试验,将转移灶≤5个的患者按1:1的比例随机分配给MDT加全身治疗与全身治疗。疾病进展的定义是放射学标准(RECIST v1.1)、临床进展或死亡。主要终点是所有患者随访至少 6 个月后按方案人群的 PFS。探索性终点包括全身免疫反应指标:2019年3月19日至2023年2月13日期间,41名患者被随机分配,40名患者符合PFS主要分析条件(MDT组19名患者;对照组21名患者)。中位随访时间为17个月,MDT治疗组的中位PFS时间为10.3个月(95% CI,4.6-14.0),对照组为2.5个月(95% CI,1.7-5.1)。在全身治疗基础上加用MDT可明显改善PFS(分层对数秩检验P = .030),危险比为0.43(95% CI,0.20至0.94)。未观察到与MDT相关的≥3级或更严重的不良事件。全身免疫激活事件与MDT有关,并与PFS的改善相关:本研究支持对少转移性PDAC患者在全身治疗的基础上加用MDT。诱导全身免疫是一种可能的获益机制。这些结果值得进行确证试验,以完善治疗策略并提供外部验证。
{"title":"Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.","authors":"Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, Marina N Medina-Rosales, Alexandre Reuben, Emma B Holliday, Grace L Smith, Sonal S Noticewala, Sarah Nicholas, Tracy R Price, Rachael M Martin-Paulpeter, Luis A Perles, Sunyoung S Lee, Michael S Lee, Brandon G Smaglo, Ryan W Huey, Jason Willis, Dan Zhao, Lorenzo Cohen, Cullen M Taniguchi, Eugene J Koay, Matthew H G Katz, Robert A Wolff, Prajnan Das, Shubham Pant, Albert C Koong, Chad Tang","doi":"10.1200/JCO.24.00081","DOIUrl":"10.1200/JCO.24.00081","url":null,"abstract":"<p><strong>Purpose: </strong>The EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>EXTEND (ClinicalTrials.gov identifier: NCT03599765) is a multicenter, phase II basket trial randomly assigning patients with ≤five metastases 1:1 to MDT plus systemic therapy versus systemic therapy. Disease progression was defined by radiologic criteria (RECIST v1.1), clinical progression, or death. The primary end point was PFS in the per-protocol population, evaluated after all patients achieved at least 6 months of follow-up. Exploratory end points included systemic immune response measures.</p><p><strong>Results: </strong>Between March 19, 2019, and February 13, 2023, 41 patients were randomly assigned and 40 were eligible for the primary analysis of PFS (19 patients in the MDT arm; 21 patients in the control arm). At a median follow-up time of 17 months, the median PFS time was 10.3 months (95% CI, 4.6 to 14.0) in the MDT arm versus 2.5 months (95% CI, 1.7 to 5.1) in the control arm. PFS was significantly improved by the addition of MDT to systemic therapy (<i>P</i> = .030 for stratified log-rank test) with a hazard ratio of 0.43 (95% CI, 0.20 to 0.94). No grade ≥3 or greater adverse events related to MDT were observed. Systemic immune activation events were associated with MDT and correlated with improved PFS.</p><p><strong>Conclusion: </strong>This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies. Equipoise Lost?突破性疗法时代的试验行为挑战。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-09-17 DOI: 10.1200/JCO-24-01200
Jaleh Fallah, Flora Mulkey, Mallorie H Fiero, Haley Gittleman, Chi Song, Jeevan Puthiamadathil, Anup Amatya, Sundeep Agrawal, Paz Vellanki, Daniel L Suzman, Harpreet Singh, Laleh Amiri-Kordestani, Pallavi Mishra-Kalyani, Richard Pazdur, Paul G Kluetz

FDA Oncology Center's @Falleh_Fallah and colleagues discuss loss of equipoise and other trial conduct challenges in an era of breakthrough therapies - via @JCO_ASCO.

FDA 肿瘤中心的 @Falleh_Fallah 及其同事讨论了突破性疗法时代的平衡损失和其他试验行为挑战 - via @JCO_ASCO。
{"title":"Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies.","authors":"Jaleh Fallah, Flora Mulkey, Mallorie H Fiero, Haley Gittleman, Chi Song, Jeevan Puthiamadathil, Anup Amatya, Sundeep Agrawal, Paz Vellanki, Daniel L Suzman, Harpreet Singh, Laleh Amiri-Kordestani, Pallavi Mishra-Kalyani, Richard Pazdur, Paul G Kluetz","doi":"10.1200/JCO-24-01200","DOIUrl":"10.1200/JCO-24-01200","url":null,"abstract":"<p><p>FDA Oncology Center's @Falleh_Fallah and colleagues discuss loss of equipoise and other trial conduct challenges in an era of breakthrough therapies - via @JCO_ASCO.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural Racism and Treatment Delay Among Black and White Patients With Breast Cancer. 结构性种族主义与黑人和白人乳腺癌患者的治疗延迟。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-08-06 DOI: 10.1200/JCO.23.02483
Katherine E Reeder-Hayes, Bradford E Jackson, Tzy-Mey Kuo, Chris D Baggett, Juan Yanguela, Matthew R LeBlanc, Mya L Roberson, Stephanie B Wheeler

Purpose: Structural racism (SR) is a potential driver of health disparities, but research quantifying its impacts on cancer outcomes has been limited. We aimed to develop a multidimensional county-level SR measure and to examine the association of SR with breast cancer (BC) treatment delays among Black and White patients.

Methods: The cohort included 32,095 individuals from the North Carolina Central Cancer Registry with stage I to III BC diagnosed between 2004 and 2017 and linked to multipayer insurance claims from the Cancer Information and Population Health Resource. County-level data were drawn from multiple public sources aggregated in the Robert Wood Johnson County Health Rankings database. Racial gaps in eight social determinants across five domains were quantified at the county level and ranked on a 0-100 minimum-maximum scale. Domain scores were averaged to create a SR Composite Index (SRCI) score. We used multilevel logistic regression with random intercepts and multiple cross-level interaction terms to evaluate the association between county-level SRCI and patient-level treatment delays, adjusting for patient-level characteristics and stratified by race.

Results: The SRCI score ranged from 21 to 75 with a median (IQR) of 39.0 (31.8, 45.7). For Black patients, a 10-unit increase in SRCI score was associated with increased odds of delay (Adjusted odds ratios [aOR], 1.25; 95% confidence limits [CL], 1.08 to 1.45). No such association was found for White patients (OR, 1.05; 95% CL, 0.97 to 1.15).

Conclusion: Area-level SR measured by a composite index is associated with higher odds of BC treatment delays among Black, but not White patients. Increasing county-level SR is associated with increasing Black-White disparities in treatment delay. Further research is needed to refine the measurement of SR and to examine its association with other cancer care disparities.

目的:结构性种族主义(SR)是健康差异的潜在驱动因素,但量化其对癌症结果影响的研究却很有限。我们旨在开发一种多维度的县级 SR 测量方法,并研究黑人和白人患者中 SR 与乳腺癌(BC)治疗延迟的关系:研究队列包括北卡罗来纳州中央癌症登记处的 32,095 名患者,他们在 2004 年至 2017 年期间确诊为 I 期至 III 期乳腺癌,并与癌症信息和人口健康资源的多方保险索赔相关联。县级数据来自罗伯特-伍德-约翰逊县健康排名数据库汇总的多个公共来源。在县一级对五个领域中八个社会决定因素的种族差距进行了量化,并按 0-100 最小值-最大值进行排序。各领域得分取平均值,得出 SR 综合指数 (SRCI) 分值。我们使用带有随机截距和多个跨级别交互项的多级别逻辑回归来评估县级 SRCI 与患者级别治疗延迟之间的关联,同时对患者级别特征进行调整并按种族进行分层:SRCI得分介于21到75之间,中位数(IQR)为39.0(31.8,45.7)。对于黑人患者,SRCI 分数每增加 10 个单位,延迟的几率就会增加(调整后的几率比 [aOR],1.25;95% 置信区间 [CL],1.08 至 1.45)。白人患者没有发现这种关联(OR,1.05;95% CL,0.97 至 1.15):结论:以综合指数衡量的地区级SR与黑人而非白人患者出现BC治疗延迟的几率较高有关。县级 SR 的增加与黑人和白人治疗延迟差异的增加有关。还需要进一步研究来完善SR的测量方法,并检查其与其他癌症治疗差异的关联。
{"title":"Structural Racism and Treatment Delay Among Black and White Patients With Breast Cancer.","authors":"Katherine E Reeder-Hayes, Bradford E Jackson, Tzy-Mey Kuo, Chris D Baggett, Juan Yanguela, Matthew R LeBlanc, Mya L Roberson, Stephanie B Wheeler","doi":"10.1200/JCO.23.02483","DOIUrl":"10.1200/JCO.23.02483","url":null,"abstract":"<p><strong>Purpose: </strong>Structural racism (SR) is a potential driver of health disparities, but research quantifying its impacts on cancer outcomes has been limited. We aimed to develop a multidimensional county-level SR measure and to examine the association of SR with breast cancer (BC) treatment delays among Black and White patients.</p><p><strong>Methods: </strong>The cohort included 32,095 individuals from the North Carolina Central Cancer Registry with stage I to III BC diagnosed between 2004 and 2017 and linked to multipayer insurance claims from the Cancer Information and Population Health Resource. County-level data were drawn from multiple public sources aggregated in the Robert Wood Johnson County Health Rankings database. Racial gaps in eight social determinants across five domains were quantified at the county level and ranked on a 0-100 minimum-maximum scale. Domain scores were averaged to create a SR Composite Index (SRCI) score. We used multilevel logistic regression with random intercepts and multiple cross-level interaction terms to evaluate the association between county-level SRCI and patient-level treatment delays, adjusting for patient-level characteristics and stratified by race.</p><p><strong>Results: </strong>The SRCI score ranged from 21 to 75 with a median (IQR) of 39.0 (31.8, 45.7). For Black patients, a 10-unit increase in SRCI score was associated with increased odds of delay (Adjusted odds ratios [aOR], 1.25; 95% confidence limits [CL], 1.08 to 1.45). No such association was found for White patients (OR, 1.05; 95% CL, 0.97 to 1.15).</p><p><strong>Conclusion: </strong>Area-level SR measured by a composite index is associated with higher odds of BC treatment delays among Black, but not White patients. Increasing county-level SR is associated with increasing Black-White disparities in treatment delay. Further research is needed to refine the measurement of SR and to examine its association with other cancer care disparities.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: CML and the WHO: Why? 勘误:CML 与世界卫生组织:为什么?
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-10-04 DOI: 10.1200/JCO-24-02083
{"title":"Erratum: CML and the WHO: Why?","authors":"","doi":"10.1200/JCO-24-02083","DOIUrl":"10.1200/JCO-24-02083","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. 斯德哥尔摩3多种族前列腺癌检测队列(SEPTA):一项前瞻性多中心试验。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-07-22 DOI: 10.1200/JCO.24.00152
Hari T Vigneswaran, Martin Eklund, Andrea Discacciati, Tobias Nordström, Rebecca A Hubbard, Nathan Perlis, Michael R Abern, Daniel M Moreira, Scott Eggener, Paul Yonover, Alexander K Chow, Kara Watts, Michael A Liss, Gregory R Thoreson, Andre L Abreu, Geoffrey A Sonn, Thorgerdur Palsdottir, Anna Plym, Fredrik Wiklund, Henrik Grönberg, Adam B Murphy

Purpose: Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort.

Methods: An observational prospective multicentered (17 sites) clinical trial (2019-2023), supplemented by prospectively recruited participants (2008-2020) in a urology clinic setting included men with suspicion of PCa and underwent prostate biopsy. Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. The primary endpoint was detection of International Society of Urological Pathology (ISUP) Grade ≥2 cancer (clinically significant PCa, csPC). The two primary aims were to (1) demonstrate noninferior sensitivity (0.8 lower bound 95% CI noninferiority margin) in detecting csPC using Stockholm3 compared with PSA (relative sensitivity) and (2) demonstrate superior specificity by reducing biopsies with benign results or low-grade cancers (relative specificity).

Results: A total of 2,129 biopsied participants were included: Asian (16%, 350), Black or African American (Black; 24%, 505), Hispanic or Latino and White (Hispanic; 14%, 305), and non-Hispanic or non-Latino and White (White; 46%, 969). Overall, Stockholm3 showed noninferior sensitivity compared with PSA ≥4 ng/mL (relative sensitivity: 0.95 [95% CI, 0.92 to 0.99]) and nearly three times higher specificity (relative specificity: 2.91 [95% CI, 2.63 to 3.22]). Results were consistent across racial and ethnic subgroups: noninferior sensitivity (0.91-0.98) and superior specificity (2.51-4.70). Compared with PSA, Stockholm3 could reduce benign and ISUP 1 biopsies by 45% overall and between 42% and 52% across racial and ethnic subgroups.

Conclusion: In a substantially diverse population, Stockholm3 significantly reduces unnecessary prostate biopsies while maintaining a similar sensitivity to PSA in detecting csPC.

目的:亚裔、黑人和西班牙裔男性在前列腺癌(PCa)临床试验中的代表性不足。很少有新型前列腺癌生物标志物在不同人群中得到验证。我们旨在确定斯德哥尔摩 3 是否能提高不同人群的前列腺癌检测率:一项观察性前瞻性多中心(17 个地点)临床试验(2019-2023 年),辅以在泌尿科诊所环境中前瞻性招募的参与者(2008-2020 年),纳入了怀疑患有 PCa 并接受前列腺活检的男性。活组织检查前,收集样本以测量斯德哥尔摩3风险评分。参数包括前列腺特异性抗原(PSA)、游离 PSA、KLK2、GDF15、PSP94、种系风险(单核苷酸多态性)、年龄、家族史和既往阴性活检。主要终点是检测出国际泌尿病理学会(ISUP)≥2级癌症(有临床意义的PCa,csPC)。两个主要目的是:(1) 证明使用斯德哥尔摩3检测csPC的灵敏度(0.8下限95% CI非劣效边距)不优于PSA(相对灵敏度);(2) 通过减少良性结果或低级别癌症的活检,证明其特异性更强(相对特异性):共纳入 2,129 名活检参与者:亚裔(16%,350 人)、黑人或非裔美国人(黑人;24%,505 人)、西班牙裔或拉丁裔和白人(西班牙裔;14%,305 人)以及非西班牙裔或非拉丁裔和白人(白人;46%,969 人)。总体而言,与 PSA ≥4 ng/mL 相比,Stockholm3 的灵敏度并不逊色(相对灵敏度:0.95 [95% CI,0.92 至 0.99]),特异性则高出近三倍(相对特异性:2.91 [95% CI,2.63 至 3.22])。不同种族和民族亚群的结果一致:灵敏度(0.91-0.98)和特异性(2.51-4.70)均不低于前者。与 PSA 相比,Stockholm3 可将良性和 ISUP 1 活检率总体降低 45%,在不同种族和民族亚群中降低 42% 至 52%:结论:在大量不同的人群中,Stockholm3 能显著减少不必要的前列腺活检,同时在检测 csPC 方面保持与 PSA 相似的灵敏度。
{"title":"Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.","authors":"Hari T Vigneswaran, Martin Eklund, Andrea Discacciati, Tobias Nordström, Rebecca A Hubbard, Nathan Perlis, Michael R Abern, Daniel M Moreira, Scott Eggener, Paul Yonover, Alexander K Chow, Kara Watts, Michael A Liss, Gregory R Thoreson, Andre L Abreu, Geoffrey A Sonn, Thorgerdur Palsdottir, Anna Plym, Fredrik Wiklund, Henrik Grönberg, Adam B Murphy","doi":"10.1200/JCO.24.00152","DOIUrl":"10.1200/JCO.24.00152","url":null,"abstract":"<p><strong>Purpose: </strong>Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort.</p><p><strong>Methods: </strong>An observational prospective multicentered (17 sites) clinical trial (2019-2023), supplemented by prospectively recruited participants (2008-2020) in a urology clinic setting included men with suspicion of PCa and underwent prostate biopsy. Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. The primary endpoint was detection of International Society of Urological Pathology (ISUP) Grade ≥2 cancer (clinically significant PCa, csPC). The two primary aims were to (1) demonstrate noninferior sensitivity (0.8 lower bound 95% CI noninferiority margin) in detecting csPC using Stockholm3 compared with PSA (relative sensitivity) and (2) demonstrate superior specificity by reducing biopsies with benign results or low-grade cancers (relative specificity).</p><p><strong>Results: </strong>A total of 2,129 biopsied participants were included: Asian (16%, 350), Black or African American (Black; 24%, 505), Hispanic or Latino and White (Hispanic; 14%, 305), and non-Hispanic or non-Latino and White (White; 46%, 969). Overall, Stockholm3 showed noninferior sensitivity compared with PSA ≥4 ng/mL (relative sensitivity: 0.95 [95% CI, 0.92 to 0.99]) and nearly three times higher specificity (relative specificity: 2.91 [95% CI, 2.63 to 3.22]). Results were consistent across racial and ethnic subgroups: noninferior sensitivity (0.91-0.98) and superior specificity (2.51-4.70). Compared with PSA, Stockholm3 could reduce benign and ISUP 1 biopsies by 45% overall and between 42% and 52% across racial and ethnic subgroups.</p><p><strong>Conclusion: </strong>In a substantially diverse population, Stockholm3 significantly reduces unnecessary prostate biopsies while maintaining a similar sensitivity to PSA in detecting csPC.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. 对乳腺癌风险较高的妇女进行对比增强乳腺 X 射线摄影补充筛查的前瞻性研究:患病率调查的结果。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-07-26 DOI: 10.1200/JCO.22.02819
Bhavika K Patel, Molly B Carnahan, Donald Northfelt, Karen Anderson, Gina L Mazza, Victor J Pizzitola, Marina E Giurescu, Roxanne Lorans, William G Eversman, Richard E Sharpe, Laura K Harper, Heidi Apsey, Patricia Cronin, Juliana Kling, Brenda Ernst, Jennifer Palmieri, Jessica Fraker, Lida Mina, Felipe Batalini, Barbara Pockaj

Purpose: Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) have shown similar diagnostic performance in detection of breast cancer. Limited CEM data are available for high-risk breast cancer screening. The purpose of the study was to prospectively investigate the efficacy of supplemental screening CEM in elevated risk patients.

Materials and methods: A prospective, single-institution, institutional review board-approved observational study was conducted in asymptomatic elevated risk women age 35 years or older who had a negative conventional two-dimensional digital breast tomosynthesis screening mammography (MG) and no additional supplemental screening within the prior 12 months.

Results: Four hundred sixty women were enrolled from February 2019 to April 2021. The median age was 56.8 (range, 35.0-79.2) years; 408 of 460 (88.7%) were mammographically dense. Biopsy revealed benign changes in 22 women (22/37, 59%), high-risk lesions in four women (4/37, 11%), and breast cancer in 11 women (11/37, 30%). Fourteen cancers (10 invasive, tumor size range 4-15 mm, median 9 mm) were diagnosed in 11 women. The overall supplemental cancer detection rate was 23.9 per 1,000 patients, 95% CI (12.0 to 42.4). All cancers were grade 1 or 2, ER+ ERBB2-, and node negative. CEM imaging screening offered high specificity (0.875 [95% CI, 0.844 to 0.906]), high NPV (0.998 [95% CI, 0.993 to 1.000), moderate PPV1 (0.164 [95% CI, 0.076 to 0.253), moderate PPV3 (0.275 [95% CI, 0.137 to 0.413]), and high sensitivity (0.917 [95% CI, 0.760 to 1.000]). At least 1 year of imaging follow-up was available on all patients, and one interval cancer was detected on breast MRI 4 months after negative screening CEM.

Conclusion: A pilot trial demonstrates a supplemental cancer detection rate of 23.9 per 1,000 in women at an elevated risk for breast cancer. Larger, multi-institutional, multiyear CEM trials in patients at elevated risk are needed for validation.

目的:对比增强乳腺 X 光造影术(CEM)和磁共振成像(MRI)在检测乳腺癌方面显示出相似的诊断性能。用于高危乳腺癌筛查的 CEM 数据有限。本研究旨在前瞻性地调查高危患者补充筛查 CEM 的疗效:这项前瞻性、单一机构、机构审查委员会批准的观察性研究针对35岁或35岁以上、常规二维数字乳腺断层合成筛查乳腺X线摄影(MG)呈阴性且在之前12个月内未进行额外补充筛查的无症状高危女性:从 2019 年 2 月到 2021 年 4 月,共有 4600 名妇女参加了此次筛查。中位年龄为 56.8 岁(35.0-79.2 岁);460 名女性中有 408 名(88.7%)乳腺组织致密。活检结果显示,22 名女性(22/37,59%)为良性病变,4 名女性(4/37,11%)为高危病变,11 名女性(11/37,30%)为乳腺癌。11 名妇女中确诊了 14 例癌症(10 例为浸润性,肿瘤大小范围为 4-15 毫米,中位数为 9 毫米)。癌症总补充检测率为每千名患者 23.9 例,95% CI (12.0 至 42.4)。所有癌症均为 1 级或 2 级、ER+ ERBB2-、结节阴性。CEM成像筛查具有高特异性(0.875 [95% CI, 0.844 to 0.906])、高NPV(0.998 [95% CI, 0.993 to 1.000])、中度PPV1(0.164 [95% CI, 0.076 to 0.253])、中度PPV3(0.275 [95% CI, 0.137 to 0.413])和高灵敏度(0.917 [95% CI, 0.760 to 1.000])。所有患者都接受了至少一年的影像学随访,其中一名患者在CEM筛查阴性后4个月通过乳腺核磁共振检查发现了间期癌:一项试点试验表明,在乳腺癌风险较高的妇女中,癌症补充检测率为 23.9‰。需要对高危患者进行更大规模、多机构、多年期的 CEM 试验,以进行验证。
{"title":"Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.","authors":"Bhavika K Patel, Molly B Carnahan, Donald Northfelt, Karen Anderson, Gina L Mazza, Victor J Pizzitola, Marina E Giurescu, Roxanne Lorans, William G Eversman, Richard E Sharpe, Laura K Harper, Heidi Apsey, Patricia Cronin, Juliana Kling, Brenda Ernst, Jennifer Palmieri, Jessica Fraker, Lida Mina, Felipe Batalini, Barbara Pockaj","doi":"10.1200/JCO.22.02819","DOIUrl":"10.1200/JCO.22.02819","url":null,"abstract":"<p><strong>Purpose: </strong>Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) have shown similar diagnostic performance in detection of breast cancer. Limited CEM data are available for high-risk breast cancer screening. The purpose of the study was to prospectively investigate the efficacy of supplemental screening CEM in elevated risk patients.</p><p><strong>Materials and methods: </strong>A prospective, single-institution, institutional review board-approved observational study was conducted in asymptomatic elevated risk women age 35 years or older who had a negative conventional two-dimensional digital breast tomosynthesis screening mammography (MG) and no additional supplemental screening within the prior 12 months.</p><p><strong>Results: </strong>Four hundred sixty women were enrolled from February 2019 to April 2021. The median age was 56.8 (range, 35.0-79.2) years; 408 of 460 (88.7%) were mammographically dense. Biopsy revealed benign changes in 22 women (22/37, 59%), high-risk lesions in four women (4/37, 11%), and breast cancer in 11 women (11/37, 30%). Fourteen cancers (10 invasive, tumor size range 4-15 mm, median 9 mm) were diagnosed in 11 women. The overall supplemental cancer detection rate was 23.9 per 1,000 patients, 95% CI (12.0 to 42.4). All cancers were grade 1 or 2, ER+ ERBB2-, and node negative. CEM imaging screening offered high specificity (0.875 [95% CI, 0.844 to 0.906]), high NPV (0.998 [95% CI, 0.993 to 1.000), moderate PPV1 (0.164 [95% CI, 0.076 to 0.253), moderate PPV3 (0.275 [95% CI, 0.137 to 0.413]), and high sensitivity (0.917 [95% CI, 0.760 to 1.000]). At least 1 year of imaging follow-up was available on all patients, and one interval cancer was detected on breast MRI 4 months after negative screening CEM.</p><p><strong>Conclusion: </strong>A pilot trial demonstrates a supplemental cancer detection rate of 23.9 per 1,000 in women at an elevated risk for breast cancer. Larger, multi-institutional, multiyear CEM trials in patients at elevated risk are needed for validation.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141766151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). 前瞻性随机 AATT 研究(外周 T 细胞淋巴瘤患者的自体或异体移植)的长期随访。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-09-13 DOI: 10.1200/JCO.24.00554
Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, Kamal Bouabdallah, Mathieu Leclerc, Guillaume Cartron, Pascal Turlure, Peter Reimer, Eva Wagner-Drouet, Laurence Sanhes, Roch Houot, Murielle Roussel, Frank Kroschinsky, Peter Dreger, Andreas Viardot, Laurence de Leval, Andreas Rosenwald, Philippe Gaulard, Gerald Wulf, Alban Villate, Christelle Latiere, Ahmet Elmaagacli, Bertram Glass, Viola Poeschel, Gandhi Damaj, David Sibon, Eric Durot, Karin Bilger, Anne Banos, Mathias Haenel, Martin Dreyling, Ulrich Keller, Mourad Tiab, Bernard Drenou, Jérome Cornillon, Stéphanie Nguyen, Marie Robin, Maike Nickelsen, Lorenz Trümper, Georg Lenz, Marita Ziepert, Norbert Schmitz

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26) or autoSCT (n = 41) on study, the cumulative progression/relapse rate was 8% (95% CI, 0 to 19) and 55% (95% CI, 35 to 74). Nonrelapse mortality (NRM) was 31% (95% CI, 13 to 49) and 3% (95% CI, 0 to 8) after alloSCT and autoSCT, respectively. Fifteen of 30 patients with early progression and 11 of 20 patients with progression/relapse after autoSCT received alloSCT. Seven-year OS after salvage alloSCT was 61% (95% CI, 47 to 74); NRM was 23% (95% CI, 6 to 40). Long-term follow-up documents the strong graft versus lymphoma effect of alloSCT independent of the timing of transplantation. Survival of patients unable to undergo transplantation was dismal. AlloSCT is the treatment of choice for younger, transplant-eligible patients with relapsed/refractory PTCL. AlloSCT is currently not recommended as part of first-line consolidation.

临床试验经常包括多个终点,这些终点在不同时间成熟。最初的报告通常以主要终点为基础,可能会在关键的计划共同主要分析或次级分析尚未完成时发布。III期随机AATT研究的初步分析显示,外周T细胞淋巴瘤(PTCL)年轻患者接受自体或异体移植(alloSCT)治疗后,无事件生存期(EFS)和总生存期(OS)相似。随机分配接受异体干细胞移植的患者七年无事件生存率为38%(95% CI,25至52),而随机分配接受自体造血干细胞移植(autoSCT)的患者七年无事件生存率为34%(95% CI,22至47);OS为55%(95% CI,41至69)和61%(95% CI,47至74)。在接受alloSCT(26人)或autoSCT(41人)治疗的患者中,累积进展/复发率分别为8%(95% CI,0至19)和55%(95% CI,35至74)。alloSCT和autoSCT后的非复发死亡率(NRM)分别为31%(95% CI,13-49)和3%(95% CI,0-8)。30例早期进展患者中有15例接受了异体干细胞移植,20例自体干细胞移植后进展/复发患者中有11例接受了异体干细胞移植。挽救性异体移植后的7年OS为61%(95% CI,47-74);NRM为23%(95% CI,6-40)。长期随访结果表明,异体干细胞移植对淋巴瘤有很强的移植物抗淋巴瘤效应,与移植时机无关。无法接受移植的患者生存率很低。对于年龄较小、符合移植条件的复发/难治性 PTCL 患者,异体干细胞移植是首选治疗方法。目前不推荐将异体干细胞移植作为一线巩固治疗的一部分。
{"title":"Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).","authors":"Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, Kamal Bouabdallah, Mathieu Leclerc, Guillaume Cartron, Pascal Turlure, Peter Reimer, Eva Wagner-Drouet, Laurence Sanhes, Roch Houot, Murielle Roussel, Frank Kroschinsky, Peter Dreger, Andreas Viardot, Laurence de Leval, Andreas Rosenwald, Philippe Gaulard, Gerald Wulf, Alban Villate, Christelle Latiere, Ahmet Elmaagacli, Bertram Glass, Viola Poeschel, Gandhi Damaj, David Sibon, Eric Durot, Karin Bilger, Anne Banos, Mathias Haenel, Martin Dreyling, Ulrich Keller, Mourad Tiab, Bernard Drenou, Jérome Cornillon, Stéphanie Nguyen, Marie Robin, Maike Nickelsen, Lorenz Trümper, Georg Lenz, Marita Ziepert, Norbert Schmitz","doi":"10.1200/JCO.24.00554","DOIUrl":"10.1200/JCO.24.00554","url":null,"abstract":"<p><p><i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26) or autoSCT (n = 41) on study, the cumulative progression/relapse rate was 8% (95% CI, 0 to 19) and 55% (95% CI, 35 to 74). Nonrelapse mortality (NRM) was 31% (95% CI, 13 to 49) and 3% (95% CI, 0 to 8) after alloSCT and autoSCT, respectively. Fifteen of 30 patients with early progression and 11 of 20 patients with progression/relapse after autoSCT received alloSCT. Seven-year OS after salvage alloSCT was 61% (95% CI, 47 to 74); NRM was 23% (95% CI, 6 to 40). Long-term follow-up documents the strong graft versus lymphoma effect of alloSCT independent of the timing of transplantation. Survival of patients unable to undergo transplantation was dismal. AlloSCT is the treatment of choice for younger, transplant-eligible patients with relapsed/refractory PTCL. AlloSCT is currently not recommended as part of first-line consolidation.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis. 肿瘤亚型对黑人和白人女性乳腺癌生存率的种族差异:系统回顾与元分析》。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-09-17 DOI: 10.1200/JCO.23.02311
Juliana M Torres, Michelle O Sodipo, Margaret F Hopkins, Paulette D Chandler, Erica T Warner

Purpose: Despite effective early-detection approaches and innovative treatments, Black women in the United States have higher breast cancer mortality rates compared with White women. The purpose of this systematic review and meta-analysis is to determine the extent of disparities in breast cancer survival between Black and White women according to tumor subtype.

Methods: A comprehensive database search was performed for full-text, English-language articles published from January 1, 2000, to December 31, 2022. Included studies compared survival between Black and White female patients with breast cancer within subtypes defined by hormone receptor and human epidermal growth factor receptor 2 (HER2)/neu (HER2; now known as ERBB2) status. Random-effects models were used to combine study-specific results and generate pooled relative risks (RRs) and 95% CIs for breast cancer-specific or overall survival (OS). A protocol for this review was registered in PROSPERO (CRD42021268212).

Results: Eighteen studies including 228,885 (34,262 Black; 182,466 White) patients with breast cancer were identified. Compared with White women, Black women had a higher risk of breast cancer death for all tumor subtypes. The summary risk of breast cancer death was 50% higher among hormone receptor-positive HER2-negative [HER2-] tumors (RR, 1.50 [95% CI, 1.30 to 1.72]), 34% higher for hormone receptor+/HER2+ (RR, 1.34 [95% CI, 1.10 to 1.64]), 20% higher for hormone receptor-negative (-)/HER2+ (RR, 1.29 [95% CI, 1.00 to 1.43]), and 17% higher among individuals with hormone receptor-/HER2- tumors (hazard ratio, 1.17; 95% CI, 1.10 to 1.25). Black women also had poorer OS than White women for all subtypes.

Conclusion: These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.

目的:尽管采用了有效的早期检测方法和创新的治疗方法,美国黑人妇女的乳腺癌死亡率仍高于白人妇女。本系统综述和荟萃分析的目的是根据肿瘤亚型确定黑人和白人女性乳腺癌生存率的差异程度:方法:对 2000 年 1 月 1 日至 2022 年 12 月 31 日期间发表的全文英文文章进行了全面的数据库检索。所纳入的研究比较了根据激素受体和人类表皮生长因子受体 2 (HER2)/neu (HER2; 现称为 ERBB2) 状态定义的亚型中黑人和白人女性乳腺癌患者的生存率。随机效应模型用于合并研究的特异性结果,并生成乳腺癌特异性或总生存期(OS)的汇总相对风险系数(RRs)和 95% CIs。本综述的方案已在 PROSPERO(CRD42021268212)上注册:结果:共确定了 18 项研究,包括 228,885 名(34,262 名黑人;182,466 名白人)乳腺癌患者。与白人女性相比,黑人女性在所有肿瘤亚型中的乳腺癌死亡风险都更高。激素受体阳性 HER2 阴性 [HER2-] 肿瘤的乳腺癌死亡风险总和高出 50%(RR,1.50 [95% CI,1.30 至 1.72]),激素受体+/HER2+肿瘤的死亡风险高出 34%(RR,1.34 [95% CI,1.10至1.64])高出34%,激素受体阴性(-)/HER2+高出20%(RR,1.29 [95% CI,1.00至1.43]),激素受体-/HER2-肿瘤患者高出17%(危险比,1.17;95% CI,1.10至1.25)。在所有亚型中,黑人女性的OS也比白人女性差:这些结果表明,造成黑人和白人女性乳腺癌生存率差异的既有亚型特异性机制,也有亚型非特异性机制。
{"title":"Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.","authors":"Juliana M Torres, Michelle O Sodipo, Margaret F Hopkins, Paulette D Chandler, Erica T Warner","doi":"10.1200/JCO.23.02311","DOIUrl":"10.1200/JCO.23.02311","url":null,"abstract":"<p><strong>Purpose: </strong>Despite effective early-detection approaches and innovative treatments, Black women in the United States have higher breast cancer mortality rates compared with White women. The purpose of this systematic review and meta-analysis is to determine the extent of disparities in breast cancer survival between Black and White women according to tumor subtype.</p><p><strong>Methods: </strong>A comprehensive database search was performed for full-text, English-language articles published from January 1, 2000, to December 31, 2022. Included studies compared survival between Black and White female patients with breast cancer within subtypes defined by hormone receptor and human epidermal growth factor receptor 2 (HER2)/neu (HER2; now known as ERBB2) status. Random-effects models were used to combine study-specific results and generate pooled relative risks (RRs) and 95% CIs for breast cancer-specific or overall survival (OS). A protocol for this review was registered in PROSPERO (CRD42021268212).</p><p><strong>Results: </strong>Eighteen studies including 228,885 (34,262 Black; 182,466 White) patients with breast cancer were identified. Compared with White women, Black women had a higher risk of breast cancer death for all tumor subtypes. The summary risk of breast cancer death was 50% higher among hormone receptor-positive HER2-negative [HER2-] tumors (RR, 1.50 [95% CI, 1.30 to 1.72]), 34% higher for hormone receptor+/HER2+ (RR, 1.34 [95% CI, 1.10 to 1.64]), 20% higher for hormone receptor-negative (-)/HER2+ (RR, 1.29 [95% CI, 1.00 to 1.43]), and 17% higher among individuals with hormone receptor-/HER2- tumors (hazard ratio, 1.17; 95% CI, 1.10 to 1.25). Black women also had poorer OS than White women for all subtypes.</p><p><strong>Conclusion: </strong>These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to M. Boileau et al. 对 M. Boileau 等人的答复
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-08-02 DOI: 10.1200/JCO-24-01365
Christopher A Barker, Sue S Yom
{"title":"Reply to M. Boileau et al.","authors":"Christopher A Barker, Sue S Yom","doi":"10.1200/JCO-24-01365","DOIUrl":"10.1200/JCO-24-01365","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. 勘误:复发性胶质母细胞瘤患者奥那珠单抗加贝伐单抗与安慰剂加贝伐单抗的随机、双盲、安慰剂对照、多中心 II 期研究:疗效、安全性以及肝细胞生长因子和 O6-甲基鸟嘌呤-DNA 甲基转移酶生物标志物分析。
IF 42.1 1区 医学 Q1 ONCOLOGY Pub Date : 2024-11-10 Epub Date: 2024-10-10 DOI: 10.1200/JCO-24-02040
{"title":"Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.","authors":"","doi":"10.1200/JCO-24-02040","DOIUrl":"10.1200/JCO-24-02040","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":42.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1